Neogenix Oncology, Inc.
Records under this name other than patents Neogenix Oncology, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 8 of 8 · Back to Neogenix Oncology, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,829,678 | Recombinant Monoclonal Antibodies and Corresponding Antigens for Colon and Pancreatic Cancers Formerly held In force · High confidence | In force | High confidence | |
| US 7,763,720 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers Formerly held Term ended Term ended Aug 22, 2026 · USPTO record | Term ended | Term ended Aug 22, 2026 | USPTO record |
| US 7,314,622 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers Formerly held Term ended Term ended Apr 14, 2026 · USPTO record | Term ended | Term ended Apr 14, 2026 | USPTO record |
| US 9,605,077 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers Formerly held Term ended Ended no later than Apr 14, 2026 · USPTO record | Term ended | Ended no later than Apr 14, 2026 | USPTO record |
| US 9,034,588 | Monoclonal Antibody Therapy for Pancreas Cancer Formerly held Term ended Term ended Apr 14, 2025 · Medium confidence | Term ended | Term ended Apr 14, 2025 | Medium confidence |
| US 8,470,326 | Monoclonal Antibody Therapy for Pancreas Cancer Formerly held Term ended Term ended Jul 26, 2022 · Medium confidence | Term ended | Term ended Jul 26, 2022 | Medium confidence |
| US 7,491,801 | Identification and development of specific monoclonal antibodies to squamous cell carcinoma Lapsed on the fee record Ended Feb 17, 2013 · USPTO record | Lapsed on the fee record | Ended Feb 17, 2013 | USPTO record |
| US 5,688,657 | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor Term ended Term ended no later than Nov 18, 2017 · Low confidence | Term ended | Term ended no later than Nov 18, 2017 | Low confidence |